Exclusive Online Content
SIRION Biotech GmbH Licensed LentiBOOST™ Transduction Technology to Cellectis
Through this recent license agreement, SIRION Biotech GmbH has granted Cellectis non-exclusive right under its proprietary lentiviral transduction….
Servier & X-Chem Announce Drug Discovery Collaboration
Servier and X-Chem, Inc. recently announced a partnership to identify and develop novel small molecules for the treatment of….
Kite & Oxford BioTherapeutics Establish Cell Therapy Research Collaboration
Kite, a Gilead Company, and Oxford BioTherapeutics Ltd. recently announced the companies have entered into a research collaboration to evaluate five novel targets for a….
Argenx & Zai Lab Announce Strategic Collaboration
Argenx SE and Zai Lab Limited recently announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater China, including….
ViGeneron Signs Global Development & Commercialization Agreement With Biogen
ViGeneron GmbH recently announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat….
Radius Health Announces Commercial Agreement With Paladin Labs
Radius Health, Inc. recently announced it has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc to register, commercialize, and distribute abaloparatide on an exclusive basis in….
University of Calgary Joins the Phase 2 Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
Arch Biopartners Inc. RECENTLY announced the University of Calgary Cumming School of Medicine has joined the Phase 2 trial of its lead drug LSALT peptide (Metablok), targeting the prevention….
Ajinomoto Bio-Pharma Services & Revance Therapeutics Announce Manufacturing Agreement
Ajinomoto Bio-Pharma Services and Revance Therapeutics, Inc. recently announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for….
Vectura Earns $11-Million Milestone as Hikma Receives US FDA Approval for Generic Advair DiskusR
Vectura Group plc recently announced its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder)….
Aurinia & Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Aurinia Pharmaceuticals Inc. and Lonza recently announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build….
EXCLUSIVE ONLINE CONTENT
Premium Cell Culture Ingredients From Actylis
Download the Actylis Cell Culture Ingredients brochure to discover our product list or ask for a sample of a specific product…..
PlaqueTec & the Babraham Institute Collaborate on Early Phase Target Discovery & Development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec….
Biopharmaceutical Mega M&A Deals Surge by 71% YoY During Q1 2024
Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of….
ElevateBio Announces New US Patents for Lead Life Edit CRISPR Systems & Adenine Deaminases Enabling Advanced Gene Editing Techniques
ElevateBio is building a robust portfolio of patents protecting its novel technologies while the Company scales as the world’s first integrated genetic medicine foundry….
AbbVie & Gilgamesh Pharmaceuticals Announce Collaboration & Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders….